Agenus Inc. (AJ8)

Profile

https://www.agenusbio.com

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.